miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy

Wenjun Yin1, Yuehua Nie2, Zhiwei Zhang1

  • 1Cancer Research Institute of Medical College, University of Southern China, University Key Laboratory of Cancer Cellular and Molecular Pathology in Hunan Province, Hengyang, Hunan 421001, P.R. China.

Oncology Reports
|May 23, 2015
PubMed

Related Concept Videos